- Home
- SGN vs KTTA Comparison
SGN vs KTTA Comparison
Compare SGN & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGN | KTTA |
|---|---|---|
| Founded | 2019 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.3M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SGN | KTTA |
|---|---|---|
| Price | $0.96 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 84.1K | ★ 578.4K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $366,344.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $0.28 |
| 52 Week High | $7.24 | $3.85 |
Technical Indicators
Market Signals| Indicator | SGN | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 58.07 |
| Support Level | $1.11 | $1.09 |
| Resistance Level | $1.13 | $1.30 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 8.90 | 60.27 |
Price Performance
Historical ComparisonAbout SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).